Shanghai Henlius Biotech, Inc. (02696) said it has obtained the clinical trial application approval from the National Medical Products Administration for the new drug developed by the company - HLX55 Monoclonal Antibody for Injection used for metastatic or recurrent solid tumour treatment.
HLX55 is a bio-innovative drug that the company licensed-in from Kolltan Pharmaceuticals, Inc. for exclusive development and commercialisation in various regions across Asia and a humanised monoclonal antibody developed for targeting cMET.
全新節目《說說心理話》青少年不可以戀愛！？真實個案講述驚心動魄經歷► 即睇
